Finn
COR Healthcare distribution · Large cap · Pharma supply chain · Specialty care · Thesis updated November 8, 2026

New reporting segments highlight specialty growth despite distribution pressure

01 Running thesis

A better setup with clear growth engines

Cencora has simplified its story. In Q4 FY2026, management introduced a new two-segment reporting structure separating high-growth specialty services from foundational pharmaceutical distribution. The company is also clearing out its non-core assets, having reached an agreement to sell its equity stake in ProPharma, which effectively empties the former Other segment.

The bull case relies on the margin expansion and visibility of the new specialty segment. Cencora is aggressively scaling its physician services platform, most recently announcing an agreement to acquire a majority interest in American Oncology Network. These higher-margin acquisitions, alongside earlier additions like RCA and OneOncology, help offset pressure in the core distribution business and entrench Cencora in the fastest-growing therapeutic areas.

The bear case centers on structural headwinds in the foundational distribution segment and rising debt. While GLP-1 drugs add billions in revenue, they pressure gross margins, and structural manufacturer list price reductions persist. The core distribution business faces slower growth in fiscal 2027, pressured by previously disclosed customer losses and foreign exchange headwinds. Furthermore, customer concentration with Walgreens Boots Alliance remains a major risk given uncertainty around its new private equity ownership.

This is not a clean bargain story. The company is executing well and returning capital, including a $1.25 billion share repurchase authorization for fiscal 2027. However, the stock price demands consistent earnings growth, and the market will watch closely to see if the foundational distribution segment can reaccelerate after absorbing customer volume shifts in the year ahead.

Nov 2026▲Cencora introduced a new two-segment reporting structure and initiated fiscal 2027 adjusted EPS guidance of $19.40 to $19.75. The company also announced an agreement to acquire a majority interest in American Oncology Network and an agreement to sell its ProPharma stake.
Aug 2026▲Cencora raised its fiscal 2026 earnings guidance following outperformance by OneOncology and strong International growth. The company also announced a definitive agreement to merge MWI Animal Health with Covetrus.
May 2026▲Cencora raised full-year adjusted EPS guidance to $17.65 to $17.90 and restarted buybacks, targeting $1 billion by the end of calendar 2026. Q2 results also showed U.S. operating income up 6% and International operating income up 14%.
May 2026▲The latest 10-Q showed OneOncology already helping U.S. gross profit margin, which rose 46 basis points in Q2 FY2026. That supports the idea that higher-margin physician services can offset lower-margin GLP-1 growth.
Feb 2026→Cencora announced the $4.6 billion cash acquisition of OneOncology, increasing its push into physician services. The strategy improved the growth case but also added debt and integration risk.
Nov 2025▼The fiscal 2025 10-K added uncertainty around WBA after its private equity acquisition. It also confirmed that Walgreens and Boots together accounted for about 25% of revenue in fiscal 2025.
Aug 2025→U.S. margins kept benefiting from RCA, while GLP-1 growth slowed from earlier levels. International profitability remained weak, keeping the turnaround question open.
May 2025→The first look at RCA was positive for U.S. margin, but International operating income fell 17.3%. The thesis became more balanced between services upside and overseas weakness.
02 Business model

Moving medicines at huge scale

Cencora makes most of its money by buying medicines and healthcare products, then distributing them to pharmacies, health systems, doctors, and other providers. The business runs on very high sales volume and thin margins, so small changes in product mix or pricing can matter significantly.

Effective fiscal 2027, the company has updated its operating model to two main segments. Specialty Pharmaceutical and Provider Services focuses on high-growth areas like clinical trial logistics and physician management services. This segment aggregates platforms like OneOncology, RCA, and American Oncology Network, which target higher margins in complex care.

Pharmaceutical Distribution and Services is the foundational broad distribution business. It serves health systems, pharmacies, and international wholesale markets. While it generates the vast majority of revenue, growth here is slower, driven by volume increases in categories like GLP-1 medications that offset structural pricing pressures.

Cencora is actively pruning the business. It has entered agreements or completed divestitures for all non-core businesses formerly in its Other category, including an agreement to sell its stake in ProPharma and merge MWI Animal Health with Covetrus. This proves management is willing to exit non-core operations to focus entirely on human health distribution and specialty services.

03 Product portfolio

What flows through Cencora

Cash cow

Brand-name pharmaceuticals

These patented drugs drive high revenue through the massive distribution network, though manufacturer list price reductions can constrain profits.

Steady

Generic drugs and biosimilars

Lower-cost versions of older medicines help Cencora maintain its importance to pharmacies and health systems as patents expire.

Growth engine

Specialty pharmaceuticals

Often used for complex diseases, specialty distribution is a high-growth area increasingly supported by clinical logistics and provider services.

Growth engine

GLP-1 diabetes and weight-loss drugs

GLP-1 products continue to add billions in sales volume, though they carry lower gross profit margins than other categories.

Growth engine

Physician services platforms

Acquisitions like RCA, OneOncology, and American Oncology Network give Cencora deeper ties to community specialists and lift overall margins.

Option

Non-core and animal health products

Cencora has agreed to merge MWI Animal Health and divest ProPharma, clearing out non-core assets to focus on its pharmaceutical-centric strategy.

04 Business segments

Where revenue comes from

U.S. Healthcare Solutions89%modest
International Healthcare Solutions9%modest
Other3%declining

Segment shares use Q4 FY2026 revenue under the prior reporting structure, before intersegment eliminations. Walgreens and Boots together accounted for about 25% of fiscal 2025 revenue.

05 Risk factors

What could break the story

WBA relationship reset

High impact · Medium odds

Walgreens Boots Alliance and Boots together accounted for about 25% of Cencora revenue in fiscal 2025. WBA was acquired by Sycamore Partners in August 2025, and the new private equity owners could seek changes to long-term agreements. That could affect volumes, pricing, or contract terms.

We watchAny new WBA distribution agreement, WBA store closure updates, or Cencora comments on customer volume.

Lower-margin GLP-1 mix

Medium impact · High odds

GLP-1 drugs are a growth driver, but they have lower gross profit margins. Meanwhile, structural manufacturer list price reductions remain a consistent headwind. If GLP-1s outpace higher-margin areas, margin gains will fade.

We watchU.S. gross profit margin, GLP-1 sales growth, and comments on manufacturer price reductions.

Integration of physician networks

High impact · Medium odds

Cencora is rapidly expanding its specialty platform through debt-funded acquisitions like OneOncology and a majority stake in American Oncology Network. This introduces substantial integration complexity and leverage risk.

We watchOperating contribution from the new Specialty segment, leverage ratios, and integration costs.

Core distribution slowdown

Medium impact · Medium odds

The foundational Pharmaceutical Distribution and Services segment faces slower growth, with fiscal 2027 operating income guidance set at 2 to 4 percent due to customer volume shifts and foreign exchange headwinds.

We watchOperating income growth in the Pharmaceutical Distribution and Services segment.
06 Quick answers

In one breath

What does Cencora actually do?

Cencora distributes medicines and healthcare products to pharmacies, hospitals, doctors, and other providers. It also offers services around specialty drugs, physician practices, and global commercialization.

Why do GLP-1 drugs matter for Cencora?

GLP-1 drugs for diabetes and weight loss are driving massive sales volume through Cencora's network. The catch is that these products carry lower gross profit margins, limiting profit growth.

Why did Cencora change its reporting segments?

In late 2026, Cencora separated its business into a high-growth specialty services segment and a foundational distribution segment. The goal is to provide clearer visibility into its higher-margin specialty engine.

What is the biggest customer risk?

Walgreens and Boots together were about 25% of fiscal 2025 revenue. WBA's acquisition by private equity firm Sycamore Partners adds uncertainty around contract terms, pricing, and volume.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Cencora Q4 FY2026 earnings call transcript
  2. Cencora Q3 FY2026 Form 10-Q
  3. Cencora Q2 FY2026 Form 10-Q
  4. Cencora FY2025 Form 10-K
08 Explore the industry

Comparable Internet Content & Information companies

Companies near Cencora, Inc. in Finn's Internet Content & Information industry ranking.

Get started with Finn today